These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 16368051)

  • 1. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
    Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
    Filippatos TD; Gazi IF; Liberopoulos EN; Athyros VG; Elisaf MS; Tselepis AD; Kiortsis DN
    Atherosclerosis; 2007 Aug; 193(2):428-37. PubMed ID: 16911813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
    Nakou ES; Filippatos TD; Georgoula M; Kiortsis DN; Tselepis AD; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2008 Jul; 24(7):1919-29. PubMed ID: 18513463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.
    Florentin M; Liberopoulos EN; Filippatos TD; Kostara C; Tselepis A; Mikhailidis DP; Elisaf M
    Expert Opin Pharmacother; 2008 Nov; 9(16):2741-50. PubMed ID: 18937609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
    Filippatos TD; Liberopoulos EN; Kostapanos M; Gazi IF; Papavasiliou EC; Kiortsis DN; Tselepis AD; Elisaf MS
    Diabetes Obes Metab; 2008 Jun; 10(6):476-83. PubMed ID: 17459096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
    Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.
    Nakou ES; Filippatos TD; Kiortsis DN; Derdemezis CS; Tselepis AD; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 Dec; 9(18):3151-8. PubMed ID: 19040336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.
    Didangelos TP; Thanopoulou AK; Bousboulas SH; Sambanis CL; Athyros VG; Spanou EA; Dimitriou KC; Pappas SI; Karamanos BG; Karamitsos DT
    Curr Med Res Opin; 2004 Sep; 20(9):1393-401. PubMed ID: 15383188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
    Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
    Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
    Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
    Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic syndrome in overweight and obese schoolchildren in Beijing].
    Wan NJ; Mi J; Wang TY; Duan JL; Li M; Gong CX; Du JB; Zhao XY; Cheng H; Hou DQ; Wang L
    Zhonghua Er Ke Za Zhi; 2007 Jun; 45(6):417-21. PubMed ID: 17880785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
    Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theobromine supplementation in combination with a low-calorie diet improves cardiovascular risk factors in overweight and obese subjects with metabolic syndrome: a randomized controlled trial.
    Sharifi-Zahabi E; Rezvani N; Hajizadeh-Sharafabad F; Hosseini-Baharanchi FS; Shidfar F; Rahimi M
    Food Funct; 2023 Sep; 14(18):8431-8441. PubMed ID: 37615657
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic syndrome in nondiabetic, obese, first-degree relatives of African American patients with type 2 diabetes: African American triglycerides-HDL-C and insulin resistance paradox.
    Meis SB; Schuster D; Gaillard T; Osei K
    Ethn Dis; 2006; 16(4):830-6. PubMed ID: 17061734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.